Literature DB >> 23574101

When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed.

L Citrome1, T A Ketter.   

Abstract

Although great effort is made in clinical trials to demonstrate statistical superiority of one intervention vs. another, insufficient attention is paid regarding the clinical relevance or clinical significance of the observed outcomes. Effect sizes are not always reported. Available absolute effect size measures include Cohen's d, area under the curve, success rate difference, attributable risk and number needed to treat (NNT). Of all of these measures, NNT is arguably the most clinically intuitive and helps relate effect size difference back to real-world concerns of clinical practice. This commentary reviews the formula for NNT, and proposes acceptable values for NNT and its analogue, number needed to harm (NNH), using examples from the medical literature. The concept of likelihood to be helped or harmed (LHH), calculated as the ratio of NNH to NNT, is used to illustrate trade-offs between benefits and harms. Additional considerations in interpreting NNT are discussed, including the importance of defining acceptable response, adverse outcomes of interest, the effect of time, and the importance of individual baseline characteristics.
© 2013 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23574101     DOI: 10.1111/ijcp.12142

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  50 in total

1.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm Meeting.

Authors:  Seemal R Desai; Ilona J Frieden; Joel M Gelfand; Whitney High; Arthur Kavanaugh; Ashfaq A Marghoob; David M Ozog; Ted Rosen; Linda Stein Gold; Bruce Strober; Neil Swanson; George Martin
Journal:  J Clin Aesthet Dermatol       Date:  2015-09

2.  Quantifying clinical relevance.

Authors:  Leslie Citrome
Journal:  Innov Clin Neurosci       Date:  2014-05

3.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2016 MauiDerm Meeting based on presentations by.

Authors:  George Martin; Bruce E Strober; Craig L Leonardi; Joel M Gelfand; Andrew Blauvelt; Arthur Kavanaugh; Linda Stein Gold; Brian Berman; Ted Rosen; Eggert Stockfleth
Journal:  J Clin Aesthet Dermatol       Date:  2016-09-01

4.  Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis.

Authors:  Dimitrios Papadopoulos; Dimos-Dimitrios D Mitsikostas
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

5.  Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting.

Authors:  Jo Ann LeQuang
Journal:  J Clin Aesthet Dermatol       Date:  2017-09-01

Review 6.  Recovery after intracorporeal anastomosis in laparoscopic right hemicolectomy: a systematic review and meta-analysis.

Authors:  Marco Milone; Ugo Elmore; Andrea Vignali; Nicola Gennarelli; Michele Manigrasso; Morena Burati; Francesco Milone; Giovanni Domenico De Palma; Paolo Delrio; Riccardo Rosati
Journal:  Langenbecks Arch Surg       Date:  2017-12-12       Impact factor: 3.445

7.  Asthma and risk of breakthrough varicella infection in children.

Authors:  Puja J Umaretiya; Jennifer B Swanson; Hyo-Jin Kwon; Charles Grose; Christine M Lohse; Young J Juhn
Journal:  Allergy Asthma Proc       Date:  2016-05       Impact factor: 2.587

8.  Cost-Savings From an Antipsychotic Tablet-Splitting Program.

Authors:  Heather Carey; Mark Fondriest
Journal:  P T       Date:  2017-06

9.  Methods for Incorporating Patient Preferences for Treatments of Depression in Community Mental Health Settings.

Authors:  Paul Crits-Christoph; Robert Gallop; Caroline K Diehl; Seohyun Yin; Mary Beth Connolly Gibbons
Journal:  Adm Policy Ment Health       Date:  2017-09

Review 10.  A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach.

Authors:  Leslie Citrome
Journal:  CNS Drugs       Date:  2013-11       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.